Literature DB >> 12800236

TT virus infection in patients with chronic hepatitis B and response of TTV to lamivudine.

Javier Moreno Garcia1, Rafael Barcena Marugan, Gloria Moraleda Garcia, M Luisa-Mateos Lindeman, Jesus Fortun Abete, Santos Del-Campo Terron.   

Abstract

AIM: To investigate the responses of TT virus (TTV) and hepatitis B virus (HBV) to a long-term lamivudine therapy.
METHODS: Sixteen patients infected with both TTV and HBV were treated with lamivudine 100 mg daily for 30 months. Blood samples were drawn at the beginning of the therapy and subsequently at month 3, 6, 9, 12 and 30. Serum TTV was quantified by real time PCR and serum HBV was detected by hybridization assay and nested polymerase chain reaction.
RESULTS: TTV infection was detected in 100 % of HBV-infected patients. Loss of serum TTV DNA after one year of treatment occurred in 1/16 (6 %) patients. At the end of therapy, TTV DNA was positive in 94 % of them. The decline of HBV viremia was evident at 3 months after therapy and the response rate was 31 %, 44 %, 63 %, 50 % and 50 % at month 3, 6, 9, 12 and 30, respectively.
CONCLUSION: TTV replication is not sensitive to lamivudine and is highly prevalent in HBV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12800236      PMCID: PMC4611796          DOI: 10.3748/wjg.v9.i6.1261

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  22 in total

Review 1.  Hepatitis B virus infection.

Authors:  W M Lee
Journal:  N Engl J Med       Date:  1997-12-11       Impact factor: 91.245

2.  TT virus infection in patients with chronic hepatitis B or C: influence on clinical, histological and virological features.

Authors:  J H Kao; W Chen; P J Chen; M Y Lai; D S Chen
Journal:  J Med Virol       Date:  2000-04       Impact factor: 2.327

3.  High prevalence of TT virus (TTV) infection in patients on maintenance hemodialysis: frequent mixed infections with different genotypes and lack of evidence of associated liver disease.

Authors:  X Forns; P Hegerich; A Darnell; S U Emerson; R H Purcell; J Bukh
Journal:  J Med Virol       Date:  1999-11       Impact factor: 2.327

4.  Transfusion-associated TT virus infection and its relationship to liver disease.

Authors:  A Matsumoto; A E Yeo; J W Shih; E Tanaka; K Kiyosawa; H J Alter
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

5.  Complete circular DNA genome of a TT virus variant (isolate name SANBAN) and 44 partial ORF2 sequences implicating a great degree of diversity beyond genotypes.

Authors:  M Hijikata; K Takahashi; S Mishiro
Journal:  Virology       Date:  1999-07-20       Impact factor: 3.616

6.  Coinfection of TT virus and response to interferon therapy in patients with chronic hepatitis B or C.

Authors:  Yung-Chih Lai; Ruey-Tyng Hu; Sien-Sing Yang; Chi-Hwa Wu
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

7.  Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to alpha-interferon.

Authors:  Y Nishizawa; E Tanaka; K Orii; A Rokuhara; T Ichijo; K Yoshizawa; K Kiyosawa
Journal:  J Gastroenterol Hepatol       Date:  2000-11       Impact factor: 4.029

Review 8.  Liver disease-significant improvement with lamivudine.

Authors:  N Leung
Journal:  J Med Virol       Date:  2000-07       Impact factor: 2.327

9.  Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.

Authors:  J J Eron; S L Benoit; J Jemsek; R D MacArthur; J Santana; J B Quinn; D R Kuritzkes; M A Fallon; M Rubin
Journal:  N Engl J Med       Date:  1995-12-21       Impact factor: 91.245

10.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Authors:  C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245

View more
  3 in total

1.  Effect of SEN virus coinfection on outcome of lamivudine therapy in patients with hepatitis B.

Authors:  Dong Xu; De-Ying Tian; Zhen-Gang Zhang; Hong-Yun Chen; Pei-Hui Song
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

2.  Response of TT virus to IFN plus ribavirin treatment in patients with chronic hepatitis C.

Authors:  Javier Moreno; Gloria Moraleda; Rafael Barcena; Mluisa Mateos; Santos del Campo
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

3.  Torque Teno Midi Virus/Small Anellovirus in Sera of Healthy, HIV/HCV and HIV Infected Individuals in Lorestan Province, Iran.

Authors:  Maryam Fatholahi; Majid Bouzari
Journal:  Jundishapur J Microbiol       Date:  2015-11-21       Impact factor: 0.747

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.